Use of theophylline in neonates as an aid to ventilator weaning

C. C. Capers, E. S. Ward, John E Murphy, M. L. Job, P. A. Land

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Respiratory diseases are major causes of morbidity and mortality in premature neonates. Theophylline has been utilized as an adjunct in facilitating ventilator weaning and in the management of apnea with or without bradycardia. Patient characteristics associated with improved outcome from theophylline have not been determined. The purpose of this study was to evaluate parameters associated with improved outcome in neonates with respiratory diseases receiving theophylline. The study population consisted of premature neonates that were studied retrospectively. Criteria for entry into the study were (1) less than 40 weeks gestation, (2) a diagnosis of respiratory distress syndrome (RDS), apnea of prematurity, hyaline membrane disease (HMD), or bronchopulmonary dysplasia (BPD), (3) dependence on intermittent mandatory ventilation, (4) failure to wean from the ventilator 24 h or more before the study, or (5) receiving theophylline. In this study, we found no correlations between time to wean from the ventilator and postnatal age at the time theophylline was initiated, 5-min APGAR score, and final theophylline serum concentration before complete weaning from the ventilator. However, there were significant negative correlations between birthweight and gestational age with respect to time to wean from the ventilator. The average theophylline serum concentration before weaning from the ventilator for this population of neonates was ~5-10 μg/ml, indicating that theophylline is not beneficial as an aid to ventilator weaning at serum concentrations

Original languageEnglish (US)
Pages (from-to)471-474
Number of pages4
JournalTherapeutic Drug Monitoring
Volume14
Issue number6
StatePublished - 1992

Fingerprint

Ventilator Weaning
Theophylline
Newborn Infant
Mechanical Ventilators
Pulmonary diseases
Apnea
Serum
Hyaline Membrane Disease
Bronchopulmonary Dysplasia
Premature Mortality
Bradycardia
Population
Gestational Age
Ventilation
Morbidity
Membranes
Pregnancy

Keywords

  • Neonates
  • Pharmacokinetics
  • Theophylline
  • Ventilator

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology

Cite this

Capers, C. C., Ward, E. S., Murphy, J. E., Job, M. L., & Land, P. A. (1992). Use of theophylline in neonates as an aid to ventilator weaning. Therapeutic Drug Monitoring, 14(6), 471-474.

Use of theophylline in neonates as an aid to ventilator weaning. / Capers, C. C.; Ward, E. S.; Murphy, John E; Job, M. L.; Land, P. A.

In: Therapeutic Drug Monitoring, Vol. 14, No. 6, 1992, p. 471-474.

Research output: Contribution to journalArticle

Capers, CC, Ward, ES, Murphy, JE, Job, ML & Land, PA 1992, 'Use of theophylline in neonates as an aid to ventilator weaning', Therapeutic Drug Monitoring, vol. 14, no. 6, pp. 471-474.
Capers, C. C. ; Ward, E. S. ; Murphy, John E ; Job, M. L. ; Land, P. A. / Use of theophylline in neonates as an aid to ventilator weaning. In: Therapeutic Drug Monitoring. 1992 ; Vol. 14, No. 6. pp. 471-474.
@article{2631c510790c47d6b4e66035a5f0281c,
title = "Use of theophylline in neonates as an aid to ventilator weaning",
abstract = "Respiratory diseases are major causes of morbidity and mortality in premature neonates. Theophylline has been utilized as an adjunct in facilitating ventilator weaning and in the management of apnea with or without bradycardia. Patient characteristics associated with improved outcome from theophylline have not been determined. The purpose of this study was to evaluate parameters associated with improved outcome in neonates with respiratory diseases receiving theophylline. The study population consisted of premature neonates that were studied retrospectively. Criteria for entry into the study were (1) less than 40 weeks gestation, (2) a diagnosis of respiratory distress syndrome (RDS), apnea of prematurity, hyaline membrane disease (HMD), or bronchopulmonary dysplasia (BPD), (3) dependence on intermittent mandatory ventilation, (4) failure to wean from the ventilator 24 h or more before the study, or (5) receiving theophylline. In this study, we found no correlations between time to wean from the ventilator and postnatal age at the time theophylline was initiated, 5-min APGAR score, and final theophylline serum concentration before complete weaning from the ventilator. However, there were significant negative correlations between birthweight and gestational age with respect to time to wean from the ventilator. The average theophylline serum concentration before weaning from the ventilator for this population of neonates was ~5-10 μg/ml, indicating that theophylline is not beneficial as an aid to ventilator weaning at serum concentrations",
keywords = "Neonates, Pharmacokinetics, Theophylline, Ventilator",
author = "Capers, {C. C.} and Ward, {E. S.} and Murphy, {John E} and Job, {M. L.} and Land, {P. A.}",
year = "1992",
language = "English (US)",
volume = "14",
pages = "471--474",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Use of theophylline in neonates as an aid to ventilator weaning

AU - Capers, C. C.

AU - Ward, E. S.

AU - Murphy, John E

AU - Job, M. L.

AU - Land, P. A.

PY - 1992

Y1 - 1992

N2 - Respiratory diseases are major causes of morbidity and mortality in premature neonates. Theophylline has been utilized as an adjunct in facilitating ventilator weaning and in the management of apnea with or without bradycardia. Patient characteristics associated with improved outcome from theophylline have not been determined. The purpose of this study was to evaluate parameters associated with improved outcome in neonates with respiratory diseases receiving theophylline. The study population consisted of premature neonates that were studied retrospectively. Criteria for entry into the study were (1) less than 40 weeks gestation, (2) a diagnosis of respiratory distress syndrome (RDS), apnea of prematurity, hyaline membrane disease (HMD), or bronchopulmonary dysplasia (BPD), (3) dependence on intermittent mandatory ventilation, (4) failure to wean from the ventilator 24 h or more before the study, or (5) receiving theophylline. In this study, we found no correlations between time to wean from the ventilator and postnatal age at the time theophylline was initiated, 5-min APGAR score, and final theophylline serum concentration before complete weaning from the ventilator. However, there were significant negative correlations between birthweight and gestational age with respect to time to wean from the ventilator. The average theophylline serum concentration before weaning from the ventilator for this population of neonates was ~5-10 μg/ml, indicating that theophylline is not beneficial as an aid to ventilator weaning at serum concentrations

AB - Respiratory diseases are major causes of morbidity and mortality in premature neonates. Theophylline has been utilized as an adjunct in facilitating ventilator weaning and in the management of apnea with or without bradycardia. Patient characteristics associated with improved outcome from theophylline have not been determined. The purpose of this study was to evaluate parameters associated with improved outcome in neonates with respiratory diseases receiving theophylline. The study population consisted of premature neonates that were studied retrospectively. Criteria for entry into the study were (1) less than 40 weeks gestation, (2) a diagnosis of respiratory distress syndrome (RDS), apnea of prematurity, hyaline membrane disease (HMD), or bronchopulmonary dysplasia (BPD), (3) dependence on intermittent mandatory ventilation, (4) failure to wean from the ventilator 24 h or more before the study, or (5) receiving theophylline. In this study, we found no correlations between time to wean from the ventilator and postnatal age at the time theophylline was initiated, 5-min APGAR score, and final theophylline serum concentration before complete weaning from the ventilator. However, there were significant negative correlations between birthweight and gestational age with respect to time to wean from the ventilator. The average theophylline serum concentration before weaning from the ventilator for this population of neonates was ~5-10 μg/ml, indicating that theophylline is not beneficial as an aid to ventilator weaning at serum concentrations

KW - Neonates

KW - Pharmacokinetics

KW - Theophylline

KW - Ventilator

UR - http://www.scopus.com/inward/record.url?scp=0026475467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026475467&partnerID=8YFLogxK

M3 - Article

C2 - 1485368

AN - SCOPUS:0026475467

VL - 14

SP - 471

EP - 474

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 6

ER -